|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenues | ||||
| Cost of revenues | ||||
| Research and development, net (Note 6a) | ||||
| Impairment of product sales inventory | ||||
| GROSS PROFIT(LOSS) | ||||
| Research and development, net (Note 7.A) | ||||
| Sales and marketing expenses, net | ||||
| General and administrative expenses | ||||
| OPERATING LOSS | ||||
| Financing income (expenses), net | ||||
| Financing income (expenses), net | ||||
| LOSS BEFORE TAX EXPENSES | ||||
| Tax expenses | ||||
| NET LOSS AND TOTAL COMPREHENSIVE LOSS | ||||
| Net loss per ordinary shares, basic (in Dollars per share) | ||||
| Net loss per ordinary shares, diluted (in Dollars per share) | ||||
| Weighted average number of ordinary shares and pre-funded warrants outstanding basic (in Shares) | ||||
| Weighted average number of ordinary shares and pre-funded warrants outstanding diluted (in Shares) | ||||
Loading...